(30 days)
Not Found
No
The device description and performance studies focus on the physical properties and clinical effectiveness of a calcium alginate material for stopping nosebleeds, with no mention of AI or ML technologies.
Yes
The device is intended to stop minor nosebleeds, which is a therapeutic action addressing a health condition.
No
The device is described as being "intended to be inserted into the anterior nasal cavity to stop minor nosebleeds." Its function is therapeutic (to stop bleeding), not diagnostic (to identify or determine the nature of a disease or condition).
No
The device description clearly states it is comprised of interwoven strands of calcium alginate and is manufactured as a sheet, indicating it is a physical, material-based device, not software.
Based on the provided information, NasalCEASE™ is NOT an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is to "be inserted into the anterior nasal cavity to stop minor nosebleeds." This is a therapeutic or hemostatic function, not a diagnostic one. IVDs are used to examine specimens from the human body to provide information for diagnosis, monitoring, or screening.
- Device Description: The description details a physical material (calcium alginate) designed to be inserted into the body. This is consistent with a medical device used for treatment, not for analyzing biological samples.
- Lack of Diagnostic Elements: There is no mention of analyzing blood, tissue, or any other biological sample. There is no mention of detecting markers, measuring substances, or providing diagnostic information.
In summary, NasalCEASE™ is a medical device intended for a therapeutic purpose (stopping nosebleeds) within the body, not for performing diagnostic tests on samples taken from the body.
N/A
Intended Use / Indications for Use
NasalCEASE™ is intended to be inserted into the anterior nasal cavity to stop minor nosebleeds. It is intended to be marketed and sold as an Over-The-Counter device.
Product codes
EMX
Device Description
NasalCEASE™ is comprised of interwoven strands of calcium alginate and is manufactured as a sheet (2x4x0.5 cm) weighing approximately 20mg that can be rolled along its long or short axis and inserted into the anterior nasal cavity.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
anterior nasal cavity
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Over-The-Counter device
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A panel of physicians used the device and provided it to patients for use at home. Both physicians and patients were able to use the device correctly and effectively.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical testing. A panel of physicians used the device and provided it to patients for use at home. Both physicians and patients were able to use the device correctly and effectively.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 874.4100 Epistaxis balloon.
(a)
Identification. An epistaxis balloon is a device consisting of an inflatable balloon intended to control internal nasal bleeding by exerting pressure against the sphenopalatine artery.(b)
Classification Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 874.9.
0
JUL 01 2004
Summary Statement as defined in 21CFR 807.3
Les Laboratoires Brothier, S.A. Submitter: 41 rue de Neuilly Nanterre Paris, FRANCE 92000 Phone: 011-33-1-56 38 30 00 Fax: 011-33-1-41 20 93 70
Contact Ms. Benedicte Noury, Director of International Marketing
- Trade Name: NasalCEASETM Name: Common name: N/A Classification name: calcium alginate
Substantially Equivalent to: ENTaxis (K985069)
Description of the device: NasalCEASE™ is comprised of interwoven strands of calcium alginate and is manufactured as a sheet (2x4x0.5 cm) weighing approximately 20mg that can be rolled along its long or short axis and inserted into the anterior nasal cavity.
Intended Use: NasalCEASE™ is intended to be inserted into the anterior nasal cavity to stop minor nosebleeds. It is intended to be marketed and sold as an Over-The-Counter device.
Technological Characteristics: NasalCEASE™ is comprised of interwoven strands of calcium alginate that can be rolled along its long or short axis and inserted into the anterior nasal cavity. Upon contact with blood or other physiological fluids in the nasal cavity it adsorbs those fluids and swells to apply a compressive force. ENTaxis acts in exactly the same way.
Non-clinical testing. A panel of physicians used the device and provided it to patients for use at home. Both physicians and patients were able to use the device correctly and effectively.
Summary: The NasalCEASE™ device described in this submission is substantially equivalent to the predicate device, is safe and effective, and sufficiently simplified and explained to be sold as an OTC product.
1
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three abstract human figures facing to the right, with flowing lines representing movement or connection.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUL 0 1 2004
LES Laboratories, S.A. c/o Richard J. Freer, Ph.D. Chairman and COO 601 Biotech Drive Richmond, VA 23235
Re: K041446
Trade/Device Name: NasalCEASE™ Regulation Number: 21 CFR 874.4100 Regulation Name: Epistaxis balloon Regulatory Class: Class I Product Code: EMX Dated: May 20, 2004 Received: June 1, 2004
Dear Mr. Freer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
2
Page 2 - Richard J. Freer, Ph.D.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours.
Akalyi Rosenthal
A. Ralph Rosenthal, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
INDICATIONS FOR USE STATEMENT
| 510(k) Number: | K041446 |
|---|---|
| ---------------- | --------- |
Device Name: NasalCEASE™
Indications for Use:
This device has the following intended use.
- NasalCEASE™ is intended to be inserted into the anterior nasal cavity to stop minor nosebleeds. 1. It is intended to be marketed and sold as an Over-The-Counter device.
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109) OR
Over-The-Counter Use
Karen H. Baker
(Division Sign-Off) Division of Ophthalmic Ear Nose and Throat Devi
510(k) Number
3 I